Interleukin-12 in Treating Patients With Cancer in the Abdomen
|ClinicalTrials.gov Identifier: NCT00003046|
Recruitment Status : Completed
First Posted : February 19, 2004
Last Update Posted : July 30, 2012
RATIONALE: Interleukin-12 may kill tumor cells by stimulating a person's white blood cells to kill cancer cells.
PURPOSE: Phase I trial to study the effectiveness of interleukin-12 in treating patients with cancer in the abdomen.
|Condition or disease||Intervention/treatment||Phase|
|Anal Cancer Colorectal Cancer Gallbladder Cancer Gastric Cancer Pancreatic Cancer||Biological: Recombinant Interleukin-12||Phase 1|
OBJECTIVES: I. Determine the maximum tolerated dose of intraperitoneal interleukin-12 in patients with Mullerian carcinoma (closed to accrual as of 8/23/01), gastrointestinal carcinoma, or peritoneal mesothelioma (closed to accrual as of 8/23/01). II. Determine the qualitative and quantitative toxicity and reversibility of toxicity of this regimen in these patients.
OUTLINE: This is a dose-escalation, multicenter study. Patients receive intraperitoneal interleukin-12 over 30 minutes once weekly for 4 weeks. Treatment repeats every 4 weeks for up to 6 courses in the absence of unacceptable toxicity or disease progression. Patients with stable or responsive disease may receive an additional 6 courses. Patients receive escalating doses of intraperitoneal interleukin-12 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is established, additional patients are accrued to receive interleukin-12 at the recommended dose.
PROJECTED ACCRUAL: Approximately 20-40 patients will be accrued for this study within 2 years.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||29 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I Study of Intraperitoneal Recombinant Human Interleukin-12 (rhIL-12) in Patients With Peritoneal Carcinomatosis, Associated With Mullerian and Gastrointestinal Carcinomas|
|Study Start Date :||August 1997|
|Primary Completion Date :||October 2001|
|Study Completion Date :||October 2001|
Biological: Recombinant Interleukin-12
Intraperitoneal over 30 minutes once weekly for 4 weeks, repeats every 4 weeks for up to 6 courses
- Maximum Tolerated Dose (MTD) of Intraperitoneal Interleukin-12 [ Time Frame: 4 weeks ]MTD found in absence of unacceptable toxicity or disease progression with each 4 week treatment cycle.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00003046
|United States, Texas|
|University of Texas - MD Anderson Cancer Center|
|Houston, Texas, United States, 77030-4009|
|Study Chair:||Renato Lenzi, MD||M.D. Anderson Cancer Center|